There are plenty of options for investors on the local bourse. So many, it can be hard to decide which ones to buy over others.
To narrow things down, let's take a look at whether analysts rate the popular ASX shares below as buys right now. Here's what you need to know:
Image source: Getty Images
Life360 Inc. (ASX: 360)
Bell Potter thinks this family safety technology company could be undervalued at current levels. Last week, the broker put a buy rating and $35.50 price target on its shares.
Although Bell Potter suspects that Life360 could fall short of its monthly active user growth guidance in 2026, it hasn't made any revisions to its estimates. That's because it believes it will convert more than expected users into paid subscribers. It explains:
Despite the lowering in our global MAU growth forecast in 2026 there is no change in our revenue or earnings forecasts as, on the flip side, we have increased our conversion rate forecasts so that there is no change in our paying circle forecast for the full year. Our average forecast quarterly conversion rate – measured in crude or broad terms – has increased from 3.4% to 3.5% which is still below the average 3.6% in 2025. We are therefore still modestly below last year's level which is perhaps conservative given the addition of Pet GPS but there was an unusual spike in the conversion rate in 3Q2025 which we assume is not repeated this year.
Northern Star Resources Ltd (ASX: NST)
Bell Potter has been looking at this gold miner and sees an opportunity for investors. It has put a buy rating and $35.00 price target on its shares. The broker believes a recent share buyback signals value in the underlying business. It said:
NST announced the commencement of an on market Buy-back scheme of up to A$500m, representing ~1.6% of issued capital. The buy-back is separate from the dividend payout policy of 20-30% of cash earnings and will commence on the 23rd of April. The buy-back has minimal impact on our EPS estimates going forward, however the signalling of value in the underlying business is of more importance.
Sigma Healthcare Ltd (ASX: SIG)
Finally, Morgans has put a buy rating and $3.36 price target on this pharmacy chain operator and wholesale distributor.
It thinks investors should buy the dip after the Chemist Warehouse owner's shares pulled back recently. It explains:
SIG is a leading healthcare wholesaler, distributor and retail pharmacy franchisor with operations in Australia, NZ, Ireland and the UAE. We are forecasting ~20% EBIT growth p.a. over the next few years driven by strong LFL sales growth, store rollout (domestically and internationally), operating efficiencies and $100m p.a. synergies by FY29. Given the share price weakness, we have upgraded our recommendation to BUY (from ACCUMULATE) with an unchanged target price of $3.36 and 26% upside.
